Co-treatment with 17-DMAG (5, 10 or 20 nM) and belinostat (100, 250 or 500 nM) inhibited growth of H1650 NSCLC cells (EGFR exon 19 and PTEN mutations), greater than either inhibitor alone, with 10 nM of 17-DMAG and either 250 or 500 nM of belinostat showing synergistic antiproliferative activity (Fig. 3a, columns 12 and 15, Fig. 3b). The gene discussed is PTEN; the disease is non-small cell lung carcinoma.